The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Somnath Chatterjee
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts more than Nifty Microcap 250 and 4.7 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Somnath Chatterjee, Promoter, Chairman & Joint Managing Director of Suraksha Diagnostic Ltd, bought 8,200 equity shares through an open market purchase on 14 August 2025. His shareholding rose marginally from 26,38,768 shares (5.067%) to 26,46,968 shares (5.082%), an increase of just 0.016%. The disclosure was filed under Regulation 29(2) of SEBI's SAST Regulations, 2011. The company's total paid-up equity capital consists of 5,20,80,758 shares of ₹2 each.
This is a very small promoter purchase with negligible impact on overall shareholding, so it is unlikely to move the stock price materially. It does signal mild insider confidence, but the scale is too small to be a strong bullish indicator on its own.